Transcript of Q4 & FY26 Earnings Conference Call
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zim Laboratories reported Q4 FY26 total operating income of ~INR 1,053 million with EBITDA margin of 12.7% and PAT of INR 37 million. FY26 full-year revenue was ~INR 3,744 million, broadly flat YoY, impacted by an estimated INR 20-25 crore from MENA geopolitical disruptions and ~INR 20 crore from EU GMP-related pipeline constraints. The company substantially completed its CAPA and underwent EU GMP re-inspection (May 4-7, 2026) by German and Portuguese authorities, expecting a positive outcome. NIP and OTF contributed INR 254 million in Q4 (22% of revenue) on a sequentially improving trend. R&D spend was maintained at ~8.3% of revenue. Management projects sequential business momentum to strengthen in FY27 with commercial supplies of five approved NIP/OTF products expected from Q4 FY27 onwards, targeting NIP/OTF to eventually represent 50% of total revenue. Management guided toward upper teens EBITDA margins once regulated market commercialization scales, with 17 products in the pipeline expected to be commercialized over the next 24 months.
The EU GMP re-inspection completion and management's positive outlook signal a potential turning point; if reinstatement occurs in Q2 FY27 as expected, revenue growth and margin recovery could accelerate meaningfully from Q4 FY27 onwards. Near-term headwinds from elevated compliance costs and MENA disruptions remain but appear largely priced in.